Dr. Efrat Dotan

Hematology | Oncology
2102 Harrisburg Pike, 
Lancaster, PA 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
2102 Harrisburg Pike, 
Lancaster, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Efrat Dotan is a Hematologist and an Oncologist in Lancaster, Pennsylvania. Dr. Dotan is rated as an Experienced provider by MediFind in the treatment of DICER1 Syndrome. Her top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Familial Colorectal Cancer, and Cholangiocarcinoma (Bile Duct Cancer). Dr. Dotan is currently accepting new patients.

Her clinical research consists of co-authoring 95 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Technion - Israel Institute Of Technology
Residency
Lenox Hill Hospital
Specialties
Hematology
Oncology
Licenses
Internal Medicine in PA
Board Certifications
Medical Oncology, 2010
Fellowships
Fox Chase Cancer Center
Hospital Affiliations
Lancaster General Hospital
Temple University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

LG Health Physicians Hematology and Medical Oncology
2102 Harrisburg Pike, Lancaster, PA 17601

Additional Areas of Focus

Dr. Dotan has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Esophageal Cancer
Gallbladder Cancer
Pancreatic Cancer
Colorectal Cancer
Anal Cancer
Liver Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Window of Opportunity for Neoadjuvant Stroma Modification in Pancreatic Cancer
Window of Opportunity for Neoadjuvant Stroma Modification in Pancreatic Cancer
Enrollment Status: Recruiting
Publish Date: April 16, 2025
Intervention Type: Other, Combination product
Study Phase: Early Phase 1
A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Drug
Study Drugs: Carboplatin, Paclitaxel, Pevonedistat
Study Phase: Phase 2
Redefining The Use Of A FOLFIRINOX-Like Regimen In the Front Line In Older Patients With Metastatic Pancreatic Cancer
Redefining The Use Of A FOLFIRINOX-Like Regimen In the Front Line In Older Patients With Metastatic Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Drug
Study Phase: Phase 2
Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
Enrollment Status: Active_not_recruiting
Publish Date: November 07, 2025
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 16, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers
A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers
Enrollment Status: Completed
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drug: ZW49
Study Phase: Phase 1
Regorafenib in Adults 70 Years or Older With Metastatic Colorectal Cancer: A Phase II Study
Regorafenib in Adults 70 Years or Older With Metastatic Colorectal Cancer: A Phase II Study
Enrollment Status: Completed
Publish Date: September 04, 2024
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer
A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer
Enrollment Status: Terminated
Publish Date: January 24, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I and Randomized Phase II Study of Nab-Paclitaxel/Gemcitabine With or Without AZD1775 for Treatment of Metastatic Adenocarcinoma of the Pancreas
A Phase I and Randomized Phase II Study of Nab-Paclitaxel/Gemcitabine With or Without AZD1775 for Treatment of Metastatic Adenocarcinoma of the Pancreas
Enrollment Status: Completed
Publish Date: April 25, 2023
Intervention Type: Drug
Study Drugs: Adavosertib, Gemcitabine hydrochloride, Nab-paclitaxel
Study Phase: Phase 1/Phase 2
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Enrollment Status: Unknown
Publish Date: May 24, 2022
Intervention Type: Drug, Procedure, Radiation
Study Drugs: mFOLFIRINOX, FOLFOX
Study Phase: Phase 2
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Enrollment Status: Completed
Publish Date: September 09, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Adult Participants With Selected Advanced Solid Tumors
A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Adult Participants With Selected Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: July 31, 2020
Intervention Type: Drug
Study Phase: Phase 2
Improving the Approach to and Management of the Older Metastatic Breast Cancer Patient Via a Provider Didactic Intervention
Improving the Approach to and Management of the Older Metastatic Breast Cancer Patient Via a Provider Didactic Intervention
Enrollment Status: Completed
Publish Date: March 02, 2020
Intervention Type: Behavioral
Study Phase: Not Applicable
Phase I Study of Drug-Eluting Irinotecan Beads (DEBIRI) in Refractory Metastatic Colorectal Cancer With Liver-Only or Liver-Predominant Disease
Phase I Study of Drug-Eluting Irinotecan Beads (DEBIRI) in Refractory Metastatic Colorectal Cancer With Liver-Only or Liver-Predominant Disease
Enrollment Status: Terminated
Publish Date: February 26, 2018
Intervention Type: Procedure, Combination product
Study Phase: Phase 1
View 13 Less Clinical Trials

95 Total Publications

Prioritizing Benefit Over Tolerance Among Older Adults With Pancreatic Cancer.
Prioritizing Benefit Over Tolerance Among Older Adults With Pancreatic Cancer.
Journal: JCO oncology practice
Published: December 15, 2025
Similar Doctors
Advanced in DICER1 Syndrome
Dr. Susan M. Domchek
Oncology
Advanced in DICER1 Syndrome
Dr. Susan M. Domchek
Oncology

Rena Rowan Breast Center

3400 Civic Center Boulevard, West Pavilion, 3rd Floor, 
Philadelphia, PA 
 (62.1 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Susan Domchek is an Oncologist in Philadelphia, Pennsylvania. Dr. Domchek is rated as an Elite provider by MediFind in the treatment of DICER1 Syndrome. Her top areas of expertise are Breast Cancer, Ovarian Cancer, BRCA Positive Breast Cancer, Salpingo-Oophorectomy, and Hormone Replacement Therapy (HRT). Dr. Domchek is currently accepting new patients.

Advanced in DICER1 Syndrome
Dr. Kara N. Maxwell
Oncology
Advanced in DICER1 Syndrome
Dr. Kara N. Maxwell
Oncology

Rena Rowan Breast Center

3400 Civic Center Boulevard, West Pavilion, 3rd Floor, 
Philadelphia, PA 
 (62.1 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kara Maxwell is an Oncologist in Philadelphia, Pennsylvania. Dr. Maxwell is rated as a Distinguished provider by MediFind in the treatment of DICER1 Syndrome. Her top areas of expertise are Li-Fraumeni Syndrome, Breast Cancer, Prostate Cancer, and BRCA Positive Breast Cancer. Dr. Maxwell is currently accepting new patients.

Advanced in DICER1 Syndrome
Dr. Sundas Khan
Hematology | Oncology
Advanced in DICER1 Syndrome
Dr. Sundas Khan
Hematology | Oncology

LG Health Physicians Hematology And Medical Oncology

2102 Harrisburg Pike, 
Lancaster, PA 
 (0.1 miles away)
717-544-9400
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Sundas Khan is a Hematologist and an Oncologist in Lancaster, Pennsylvania. Dr. Khan is rated as an Advanced provider by MediFind in the treatment of DICER1 Syndrome. Her top areas of expertise are Pulmonary Embolism, DICER1 Syndrome, BRCA Positive Breast Cancer, HER2 Negative Breast Cancer, and Splenectomy. Dr. Khan is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dotan's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile